• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Clene Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    4/28/25 7:58:02 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLNN alert in real time by email
    clnn20250425_8k.htm
    false 0001822791 0001822791 2025-04-28 2025-04-28 0001822791 clnn:CommonStock00001ParValueCustomMember 2025-04-28 2025-04-28 0001822791 clnn:WarrantsToAcquireOnehalfOfOneShareOfCommonStockFor1150PerShareCustomMember 2025-04-28 2025-04-28


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT
    Pursuant to Section 13 OR 15(d)
    of The Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): April 28, 2025

    CLENE INC.
    (Exact name of registrant as specified in its charter)

     
    Delaware
    001-39834
    85-2828339
    (State or other jurisdiction
    (Commission File Number)
    (IRS Employer
    of incorporation)
     
    Identification No.)
         
    6550 South Millrock Drive, Suite G50
    Salt Lake City, Utah
     
    84121
    (Address of principal executive offices)
     
    (Zip Code)
    (801) 676-9695
    (Registrant’s telephone number, including area code)
    N/A
    (Former name or former address, if changed since last report.)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class
     
    Trading Symbol(s)
     
    Name of each exchange on which registered
    Common Stock, $0.0001 par value
     
    CLNN
     
    The Nasdaq Capital Market
    Warrants, to acquire one-fortieth of one share of Common Stock for $230.00 per share
      CLNNW  
    The Nasdaq Capital Market
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     

     
     
    Item 1.01 Entry into a Material Definitive Agreement.
     
    On April 28, 2025, Clene Inc. (the “Company”) entered into an equity distribution agreement (the “Equity Distribution Agreement”) with Canaccord Genuity LLC as placement agent (the “Placement Agent”). In accordance with the terms of the Equity Distribution Agreement, the Company may offer and sell shares of its common stock, par value $0.0001 per share (“Common Stock”), having an aggregate offering price of up to $25,000,000 from time to time through the Placement Agent. Subject to terms of the Equity Distribution Agreement, the Placement Agent is not required to sell any specific number or dollar amount of Common Stock but will act as the Company’s placement agent, using commercially reasonable efforts to sell, on the Company’s behalf, all of the Common Stock requested by the Company to be sold, consistent with the Placement Agent’s normal trading and sales practices, on terms mutually agreed between the Placement Agent and the Company. The Placement Agent will be entitled to compensation under the terms of the Equity Distribution Agreement at a fixed commission rate of 3.0% of the gross proceeds from each issuance and sale of Common Stock, if any.
     
    The issuance and sale of Common Stock, if any, by the Company under the Equity Distribution Agreement is being made pursuant to the Company’s registration statement on Form S-3 (file number 333-286058) (the “Registration Statement”), filed with the Securities and Exchange Commission (“SEC”) on March 24, 2025 and declared effective on April 25, 2025, and the Company’s prospectus supplement relating to the offering, which is expected to be filed with the SEC on April 28, 2025, that forms part of the Registration Statement.
     
    Canaccord served as placement agent for the Company’s September 2024 offering of common stock, warrants and pre-funded warrants, for which they received customary fees and expenses.
     
    A copy of the legal opinion of Holland & Knight LLP, relating to the validity of the shares in connection with the Equity Distribution Agreement is filed as Exhibit 5.1 to this Current Report on Form 8-K and is incorporated herein by reference.
     
    The foregoing description of the Equity Distribution Agreement does not purport to be complete and is qualified in its entirety by reference to the text of the Equity Distribution Agreement, which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
     
    This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Common Stock, nor shall there be any offer, solicitation or sale of the Common Shares in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
     
    Item 9.01 Financial Statements and Exhibits.
     
    (d) Exhibits
     
    Exhibit Number   Exhibit Description
    5.1   Opinion of Holland & Knight LLP.
    10.1*   Equity Distribution Agreement, Dated April 28, 2025, by and between Clene Inc. and Canaccord Genuity LLC.
    23.1   Consent of Holland & Knight LLP (contained in Exhibit 5.1).
    104   Cover Page Interactive Data File (formatted as Inline XBRL).

    *
    Schedules and similar attachments to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. We agree to furnish supplementally a copy of such omitted materials to the SEC upon request.
     
    1

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
     
     
    CLENE INC.
       
    Date: April 28, 2025
    By:
    /s/ Robert Etherington
       
    Robert Etherington
       
    President and Chief Executive Officer
     
    2
     
    Get the next $CLNN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLNN

    DatePrice TargetRatingAnalyst
    10/4/2022Outperform → Perform
    Oppenheimer
    7/18/2022$16.00Buy
    H.C. Wainwright
    5/2/2022$10.00Buy
    Canaccord Genuity
    9/28/2021$20.00Outperform
    Oppenheimer
    More analyst ratings

    $CLNN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings

      FDA provides supportive feedback on proposed statistical analysis plan for neurofilament biomarker analysis of Clene's NIH-sponsored Expanded Access ProgramNfL EAP biomarker analyses to be conducted early in the 4th Quarter of 2025 Clene confirms two additional FDA meetings scheduled for 3rd Quarter of 2025, to discuss ALS survival data and MS clinical development programSubmission of new drug application for ALS under the accelerated approval pathway on track for potential submission in the 4th Quarter of 2025 SALT LAKE CITY, June 30, 2025 (GLOBE NEWSWIRE) -- Clene, Inc. (NASDAQ:CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to ad

      6/30/25 8:00:00 AM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream

      MIAMI, May 21, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting Today, May 21, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go ba

      5/21/25 7:00:00 AM ET
      $ASPI
      $ATCH
      $CIA
      $CLNN
      Major Chemicals
      Industrials
      Finance: Consumer Services
      Finance
    • Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream

      MIAMI, May 20, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1May 21, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go back to the

      5/20/25 7:00:00 AM ET
      $ASPI
      $ATCH
      $CIA
      $CLNN
      Major Chemicals
      Industrials
      Finance: Consumer Services
      Finance